Odyssean LLC Boosts Position in Penumbra, Inc. $PEN

Odyssean LLC boosted its stake in shares of Penumbra, Inc. (NYSE:PEN) by 112.2% in the second quarter, HoldingsChannel reports. The institutional investor owned 9,328 shares of the company’s stock after purchasing an additional 4,932 shares during the period. Odyssean LLC’s holdings in Penumbra were worth $2,945,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PEN. Hsbc Holdings PLC grew its stake in Penumbra by 2.3% in the 4th quarter. Hsbc Holdings PLC now owns 1,527 shares of the company’s stock worth $475,000 after acquiring an additional 35 shares in the last quarter. Farther Finance Advisors LLC raised its stake in shares of Penumbra by 27.1% during the fourth quarter. Farther Finance Advisors LLC now owns 178 shares of the company’s stock valued at $55,000 after acquiring an additional 38 shares in the last quarter. Swiss Life Asset Management Ltd boosted its holdings in shares of Penumbra by 2.3% in the fourth quarter. Swiss Life Asset Management Ltd now owns 1,728 shares of the company’s stock valued at $537,000 after purchasing an additional 39 shares during the period. UMB Bank n.a. grew its stake in Penumbra by 11.3% in the fourth quarter. UMB Bank n.a. now owns 442 shares of the company’s stock worth $137,000 after purchasing an additional 45 shares in the last quarter. Finally, Coldstream Capital Management Inc. grew its stake in Penumbra by 6.0% in the fourth quarter. Coldstream Capital Management Inc. now owns 843 shares of the company’s stock worth $262,000 after purchasing an additional 48 shares in the last quarter. 88.88% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of equities research analysts have weighed in on PEN shares. Wall Street Zen raised Penumbra to a “hold” rating in a research report on Saturday, May 9th. Zacks Research raised Penumbra from a “strong sell” rating to a “hold” rating in a research report on Monday, August 24th. Evercore restated an “outperform” rating and set a $320.00 price target on shares of Penumbra in a research note on Monday, July 6th. Weiss Ratings restated a “hold (c)” rating on shares of Penumbra in a report on Friday, July 17th. Finally, Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a $374.00 price objective on shares of Penumbra in a research note on Thursday, June 11th. Three analysts have rated the stock with a Buy rating and fourteen have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $367.07.

Penumbra Stock Up 0.4%

Penumbra stock opened at $322.28 on Friday. The company has a quick ratio of 3.86, a current ratio of 5.75 and a debt-to-equity ratio of 0.01. The firm has a market cap of $12.69 billion, a P/E ratio of 79.18, a P/E/G ratio of 2.21 and a beta of 0.70. The business has a fifty day moving average of $321.25 and a two-hundred day moving average of $326.29. Penumbra, Inc. has a twelve month low of $221.26 and a twelve month high of $362.41.

Penumbra (NYSE:PEN) last released its quarterly earnings results on Thursday, July 30th. The company reported $0.88 EPS for the quarter, missing the consensus estimate of $1.16 by ($0.28). The company had revenue of $390.05 million during the quarter, compared to the consensus estimate of $389.64 million. Penumbra had a return on equity of 10.50% and a net margin of 10.67%.The company’s revenue was up 14.9% on a year-over-year basis. During the same period in the previous year, the firm posted $0.86 earnings per share. On average, analysts forecast that Penumbra, Inc. will post 4.96 earnings per share for the current fiscal year.

Penumbra Company Profile

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.